📋 Blood-Based Diagnosis Transforms Alzheimer's Detection
Blood tests capable of detecting Alzheimer's disease pathology with accuracy rivaling PET scans and cerebrospinal fluid analysis have reached a tipping point of clinical validation. C2N Diagnostics' PrecivityAD2 test, which measures amyloid beta 42/40 ratio and phosphorylated tau at residue 217 (p-tau217) in blood plasma, demonstrated 93% accuracy for detecting brain amyloid pathology when compared against amyloid PET scans in a primary care validation study of 1,200 patients published in JAMA Neurology in May 2026.
The test costs approximately $1,200 and is covered by Medicare for patients with cognitive impairment, though C2N is seeking FDA clearance to support broader reimbursement.
An even more disruptive development is the ALZpath p-tau217 test, developed at the University of Gothenburg and validated through Sweden's BioFINDER study across 4,500 patients. This test measures only p-tau217 using an immunoassay platform that can run on standard hospital laboratory equipment, projecting a cost of approximately $200 per test, roughly one-twentieth the cost of an amyloid PET scan and less than one-quarter of a lumbar puncture for CSF analysis.
The scalability and low cost mean that for the first time, Alzheimer's pathology can be detected in patients presenting with mild cognitive symptoms in primary care settings, not just in specialized memory clinics.
🌍 Anti-Amyloid Antibodies Scale Globally
Eli Lilly's donanemab (brand name Kisunla), approved by the FDA in July 2024, and Eisai/Biogen's lecanemab (Leqembi), approved in January 2023, have now treated over 100,000 patients combined globally. Lecanemab, which slows cognitive decline by approximately 27% over 18 months in early Alzheimer's patients, has treated over 60,000 patients primarily in the US, Japan, China, and Western Europe. The subcutaneous injection formulation, approved by the FDA in January 2026, allows patients to receive weekly injections at home after an initial intravenous loading phase, dramatically reducing infusion center burden.
Donanemab, which can be discontinued once amyloid plaques are cleared from the brain and slows decline by 35% over 76 weeks, is treating approximately 45,000 patients.
The rollout has not been without controversy. Approximately 25% of patients develop ARIA (amyloid-related imaging abnormalities), brain swelling or microhemorrhages visible on MRI, though fewer than 2% experience symptomatic cases. The FDA requires monitoring with four MRI scans during the first year of treatment.
Patient selection has been guided by APOE4 genetic testing, as carriers of the APOE4 allele have a higher risk of ARIA. Emerging real-world evidence from the Alzheimer's Disease Neuroimaging Initiative suggests that the benefit-risk ratio is most favorable for patients in the earliest stages of cognitive decline, before significant neurodegeneration has occurred.
🍎 The Prevention Frontier: Treating Before Symptoms
The most ambitious Alzheimer's trial in history, the AHEAD 3-45 study, is testing whether lecanemab can prevent Alzheimer's disease in cognitively normal individuals with elevated brain amyloid. The trial has enrolled 1,400 participants aged 55-80 who have amyloid pathology detected via PET scan but no cognitive symptoms, randomizing them to receive lecanemab or placebo for four years. Interim results are expected in 2027 and, if positive, could fundamentally recast Alzheimer's as a preventable condition managed through early detection and intervention rather than a disease diagnosed after irreversible cognitive decline.
The convergence of accurate, affordable blood tests with disease-modifying therapies has spawned a new landscape of Alzheimer's care. CVS Health and Walgreens have launched cognitive screening and blood-test programs in hundreds of retail pharmacy clinics in the US, while the Davos Alzheimer's Collaborative is deploying p-tau217 testing across 15 low and middle-income countries. The global Alzheimer's drug market is projected to reach $16 billion by 2030, with diagnostics adding $8 billion and creating what analysts at Morgan Stanley describe as the largest new therapeutic market of the century.